RO948 could distinguish patients with AD dementia from individuals without cognitive impairment and those with non-AD disorders, and the highest AUC was obtained using the I-IV ROI (AUC = 0.98 95% CI, 0.96-0.99 for AD vs no cognitive impairment and AUC = 0.97 95% CI, 0.95-0.99 for AD vs non-AD disorders), which outperformed MRI (highest AUC = 0.91 for AD vs no cognitive impairment using whole-brain thickness, and AUC = 0.80 for AD vs non-AD disorders using temporal lobe thickness) and cerebrospinal fluid measures (highest AUC = 0.94 for AD vs no cognitive impairment using Aβ42/p-tau181, and AUC = 0.93 for AD vs non-AD disorders using Aβ42/Aβ40). Retention of RO948 was higher in AD dementia compared with all other diagnostic groups. Standard uptake value ratios (SUVRs) in 4 predefined regions of interest (ROIs) reflecting Braak staging scheme for tau pathology and encompass I-II (entorhinal cortex), III-IV (inferior/middle temporal, fusiform gyrus, parahippocampal cortex, and amygdala), I-IV, and V-VI (widespread neocortical areas), area under the receiver operating characteristic curve (AUC) values, and subtraction images between RO948 and flortaucipir.ĭiagnostic groups among the 613 participants included cognitively unimpaired (mean age, 65.8 years 117 men ), mild cognitive impairment (age, 70.8 years 82 men ), AD dementia (age, 73.5 years 57 men ), and non-AD disorders (age, 70.5 years 41 men ). RO948 (all patients) and flortaucipir (3 patients with svPPA) tau PET MRI (hippocampal volume, composite temporal lobe cortical thickness, whole-brain cortical thickness) and cerebrospinal fluid measures (p-tau181 and amyloid Aβ42 and Aβ40 ratio, and Aβ42/p-tau181 ratio). Evaluation included a comparison of tau PET tracer RO948 with magnetic resonance imaging (MRI) and cerebrospinal fluid and a head-to-head comparison between RO948 and flortaucipir F 18 (flortaucipir) in patients with semantic variant primary progressive aphasia (svPPA). Participants included 257 cognitively unimpaired controls, 154 patients with mild cognitive impairment, 100 patients with AD dementia, and 102 with non-AD neurodegenerative disorders. In this diagnostic study, 613 participants in the Swedish BioFINDER-2 study were consecutively enrolled in a prospective cross-sectional study from September 4, 2017, to August 28, 2019. To examine the novel tau PET tracer RO948 F 18 (RO948) performance in discriminating Alzheimer disease (AD) from non-AD neurodegenerative disorders.
The diagnostic performance of second-generation tau positron emission tomographic (PET) tracers is not yet known.
0 kommentar(er)
